CAMBRIDGE, Mass., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Georges Gemayel, Ph.D. to its Board of Directors effective January 1, 2016. Dr. Gemayel has over 25 years of experience in the global biopharmaceutical industry including management and executive positions at biopharmaceutical companies such as Roche Labs, Genzyme and Altus Pharmaceuticals.
“I am pleased to welcome Georges to Momenta’s Board of Directors during this exciting stage in our Company’s growth,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “We believe his extensive experience in biopharmaceutical product development and commercialization will benefit the Company as we continue to advance our robust product pipeline and work toward our goal of bringing multiple products to market in the coming years.”
Dr. Gemayel has been a consultant for several biotechnology companies and venture capital funds since 2010. Prior to that he was President and CEO of Altus Pharmaceuticals from 2008 to 2009. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company's worldwide therapeutics businesses. From 1988 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs. Dr. Gemayel currently serves on the Board of Directors of the publically listed companies Raptor Pharmaceutical Corp. and Supernus Pharmaceuticals and of Dimension Therapeutics, a privately owned company. He is Chairman of the Board of Directors of privately owned biotechnology companies Orphazyme, OxThera, and Enterome Bioscience. He previously served on the Board of Directors of NPS Pharmaceuticals, Prosensa, Adolor Corporation, FoldRx, Epitherapeutics and Altus Pharmaceuticals.
Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Gemayel benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years. Forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "will," "would," "look forward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source:Momenta Pharmaceuticals, Inc.